This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta

TG Therapeutics' market cap is under $100 million, so the stock looks cheap relative to its P113K competitors. Makes total sense. It's also a bit early to conclude anything about the efficacy and safety of TG-1202 relative to its competitors, most of which are well ahead in clinical trials. Data presented last year by the company showed TG-1202 to be roughly comparable to similar drugs in terms of selectivity to the molecular target. A phase I study of TG-1202 in blood cancers started in January.

I'd be remiss if I didn't also mention the provenance of TG Therapeutics because it will surely give institutional investors with long memories some pause. TG Therapeutics was formerly Manhattan Pharmaceuticals, a Lindsay Rosenwald creation. TG's current CEO is Mike Weiss, a longtime Rosenwald lieutenant who was previously in charge of Keryx Pharmaceuticals (KERX). For every drug out of Rosenwald's stable that shows promise (Keryx's Zerenex) there are many more that end up duds.

It's an issue to think about with respect to TG-1202. Owning a drug in with a hot molecular target is not the same as developing that drug successfully. In the absence of clinical data and in the current bull market, perhaps all that matters is TG Therapeutics' cheap stock relative to its competitors. At least that's what I hear from the biotech trading Twitterati.


@MarvinOLicious tweets, "Do you think $IMUC is hiding something by reporting that of the 278 patients, only 124 qualified to be randomized?"

ImmunoCellular Therapeutics isn't hiding anything but it's silly to talk about 278 patients "enrolled" when, as you said, only 124 were actually randomized into the phase II study of its brain tumor vaccine ICT-107.

The 278 patients represent the total number screened for entry into the trial. Of that, 124 patients were accepted and randomized to ICT-107 or placebo. More than half of screened patients were excluded from the trial because they lacked specific antigens deemed favorable to ICT-107 vaccine.

ImmunoCellular enrolled 124 patients, not 278. Saying otherwise just creates unnecessary confusion. Interim results from the study are expected by the middle of the year, with final results at year's end.


3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CLDX $26.29 -3.10%
IMUC $0.58 0.66%
OSIR $17.32 -0.32%
TGTX $14.27 -2.20%
SRPT $13.28 -1.60%

Markets

DOW 18,145.45 -143.18 -0.78%
S&P 500 2,101.29 -16.10 -0.76%
NASDAQ 4,961.92 -46.1760 -0.92%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs